Brazil

| High TB burden | High HIV burden | Tuberculosis profile

Population 2009 (millions) 194 Incidence (HIV+TB in orange), notifications (black)
(rates per 100 000 population)
Rate
Estimates of burden * 2009 Number (thousands) 125
(per 100 000 pop) 100
Mortality (excluding HIV) 4 (2–7.5) 2.1 (1–3.9)
75
Prevalence (incl HIV) 96 (36–160) 50 (18–85)
50
Incidence (incl HIV) 87 (72–100) 45 (37–54)
Incidence (HIV-positive) 19 (16–23) 9.8 (8.1–12) 25
0
Case detection, all forms (%) 86 (72–100)
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008

Case notifications 2009 Prevalence (rate per 100 000 population)

New cases (%) Retreatment cases (%) 300
Smear-positive 39 267 (55) Relapse 3 340 (34)
200
Smear-negative 13 021 (18) Treatment after failure 223 (2)
Smear unknown 9 123 (13) Treatment after default 3 150 (32) 100
Extrapulmonary 10 275 (14) Other 3 105 (32)
0
Other 14 (<1)
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
Total new 71 700 Total retreatment 9 818
Total < 15 years 2 749 Mortality excluding HIV
(rate per 100 000 population)
Total new and relapse 75 040 (88% of total)
20
Total cases notified 85 159
15
Drug regimens 10
Rifampicin used throughout treatment Yes
5
% of patients treated with fixed-dose combinations (FDCs) 0 0
Paediatric formulations procured Yes 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008

Treatment success rate 2008 (%) TB/HIV 2009

New smear-positive 71 TB patients with known HIV status 39 744
New smear-negative/extrapulmonary 66 % of TB patients with known HIV status 47
Retreatment 50 TB patients that are HIV-positive 8 668
% of tested TB patients that are HIV-positive 22
Treatment success rate (%) % HIV-positive TB patients started on CPT
80 % HIV-positive TB patients started on ART 92
HIV-positive people screened for TB 8 668
40 New smear +
HIV-positive people provided with IPT
0 New smear-/extrap CPT (orange) and ART (green) for HIV-positive TB patients (blue)
Retreatment 10000
19 5
19 6
19 7
19 8
20 9
20 0
20 1
20 2
20 3
20 4
20 5
20 6
2007
08
9
9
9
9
9
0
0
0
0
0
0
0

8000
19

6000
MDR-TB, Estimates among notified cases * 2008
% of new TB cases with MDR-TB 0.90 (0.60–1.4) 4000
% of retreatment TB cases with MDR-TB 5.4 (4.1–7.2) 2000
0
Estimated MDR-TB cases among new
550 (370–860) 2003 2004 2005 2006 2007 2008 2009
pulmonary TB cases notified in 2009
Estimated MDR-TB cases among retreated
530 (400–710)
pulmonary TB cases notified in 2009

Retreat- Financing 2010 2011

MDR-TB reported cases 2009 New ment Total Total budget (US$ millions) 74 74
Cases tested for MDR-TB 0 Available funding (US$ millions) 70 69
% of notified tested for MDR-TB 0 % of budget funded 94 92
Confirmed cases of MDR-TB 397 52 449 % available funding from domestic sources 88 90
MDR-TB patients started treatment 398 % available funding from Global Fund 7 6
NTP Budget (blue) and available funding (green) (US$ millions)
Laboratories 2008 2009 2010 80
Smear (per 100 000 population) 2.1 2.1 2.1 70
Culture (per 5 million population) 5 5.8 6.9 60
DST (per 10 million population) 2 2.3 2.4 50
40
Second-line DST available In and outside country 30
National Reference Laboratory Yes 2006 2007 2008 2009 2010 2011

* Ranges represent uncertainty intervals Generated: May 10, 2011 Source: www.who.int/tb/data